Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Munn

Showing results (21-30 of 185) with videos related to

Pageof 19
Sort By:
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Seminars in Oncology|August 1, 1992
Preclinical and clinical studies of macrophage colony-stimulating factorD H Munn, N K Cheung
Trends in Molecular Medicine|January 15, 2004
IDO and tolerance to tumorsDavid H Munn, Andrew L Mellor
Seminars in Immunology|July 5, 2001
Extinguishing maternal immune responses during pregnancy: implications for immunosuppressionA L Mellor, D H Munn
Cancer Immunology, Immunotherapy : CII|July 1, 1995
Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factorD H Munn, N K Cheung
The Journal of Experimental Medicine|August 1, 1989
Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assaysD H Munn, N K Cheung
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Cancer Research|December 15, 1987
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanomaD H Munn, N K Cheung
Annual Review of Immunology|June 3, 2000
Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppressionA L Mellor, D H Munn
Pageof 19

Showing results (21-30 of 185) with videos related to

Sort By:
Pageof 19
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Seminars in Oncology|August 1, 1992
Preclinical and clinical studies of macrophage colony-stimulating factorD H Munn, N K Cheung
Trends in Molecular Medicine|January 15, 2004
IDO and tolerance to tumorsDavid H Munn, Andrew L Mellor
Seminars in Immunology|July 5, 2001
Extinguishing maternal immune responses during pregnancy: implications for immunosuppressionA L Mellor, D H Munn
Cancer Immunology, Immunotherapy : CII|July 1, 1995
Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factorD H Munn, N K Cheung
The Journal of Experimental Medicine|August 1, 1989
Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assaysD H Munn, N K Cheung
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Cancer Research|December 15, 1987
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanomaD H Munn, N K Cheung
Annual Review of Immunology|June 3, 2000
Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppressionA L Mellor, D H Munn
Pageof 19